Breast Cancer Clinical Trials in Massachusetts

Showing 121-140 of 511 trials

MARGetuximab Or Trastuzumab (MARGOT)

NCT04425018

The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)

Breast CancerStage II Breast CancerStage III Breast Cancer+1 more

Dana-Farber Cancer Institute174 participantsStarted Jul 2020

Washington D.C., District of Columbia, United States • Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States +11 more locations

RECRUITINGPhase 226 miles

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.

Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer

Puma Biotechnology, Inc.150 participantsStarted Nov 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Beverly Hills, California, United States +50 more locations

MARGetuximab Or Trastuzumab (MARGOT)

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Breast Cancer Trials in Other Cities

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)

A Study of PF-06873600 in People With Cancer

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

A Study of XMT-1660 in Participants With Solid Tumors

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Other Conditions in Massachusetts